Drug intelligence / Profile preview

CHS-3318

Development stage: Unknown
Lead developer: Coherus BioSciences
Modality: Small Molecules
Administration: Oral

Overview

CHS-3318 is an investigational small molecule antagonist of the P2X7 receptor being developed for the treatment of various inflammatory and immunological conditions. The P2X7 receptor is an ATP-gated ion channel that plays a critical role in the activation of the NLRP3 inflammasome and the subsequent release of pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and interleukin-18 (IL-18). By blocking this receptor, CHS-3318 aims to modulate the innate immune response and reduce chronic inflammation. The drug was originally part of a development agreement between Coherus BioSciences and AbbVie, though Coherus later returned the rights to the program. It has been explored for potential applications in diseases where NLRP3-mediated inflammation is a key driver.

Targets

P2RX7 (P2X purinoceptor 7)

Beyond the preview

Go deeper on CHS-3318.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHS-3318.

Explore the full profile